GlassScriptPhysician profile
Rachel Ford
NPI 1154479764
$9,265.18
in general payments reported to CMS, 2019-2025
32 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,566 · 2022: $1,465 · 2023: $2,442 · 2024: $2,033 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,976 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,975.98 |
| Education | $258.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.66 | 2021-2025 | |
| Ucb, INC. | $984.41 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $877.74 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $832.49 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $751.51 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $711.02 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $686.88 | 2021-2024 | Tremfya |
| Incyte Corporation | $491.83 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $451.29 | 2021-2025 | |
| Pfizer INC. | $398.63 | 2021-2025 | |
| Galderma Laboratories, L.P. | $341.03 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $309.81 | 2022-2025 | Jublia, Arazlo, Duobrii |
| Regeneron Healthcare Solutions, INC. | $256.16 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $134.45 | 2023-2025 | Zoryve |
| Blueprint Medicines Corporation | $122.81 | 2022-2023 | Ayvakit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $114.92 | 2023-2025 | Hadlima, Vtama |
| Leo Pharma INC. | $91.71 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $79.53 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.49 | 2023-2025 | Cyltezo, Spevigo |
| Kerecis Limited | $68.39 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Vyne Pharmaceuticals INC. | $66.30 | 2021 | |
| Genzyme Corporation | $33.25 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $31.94 | 2024 | Ycanth |
| Botanix Sb INC | $30.31 | 2025 | Sofdra |
| Acera Surgical, INC. | $22.57 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.85 | 2022 | |
| Biofrontera INC. | $19.03 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $18.35 | 2021 | |
| Mimedx Group, INC. | $17.42 | 2025 | |
| Sanofi-Aventis U.S. LLC | $16.69 | 2021 | |
| Nabriva Therapeutics, Plc | $16.41 | 2021 | |
| Strata Skin Sciences, INC. | $15.30 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.